<DOC>
	<DOCNO>NCT02141399</DOCNO>
	<brief_summary>This 52-week open-label study evaluate safety tolerability ALKS 5461 .</brief_summary>
	<brief_title>A Long-Term Safety Study ALKS 5461</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Agree use approve method contraception duration study Have potential safely benefit administration ALKS 5461 Have diagnosis major depressive disorder ( MDD ) Additional criterion may apply Have positive test drug abuse Currently pregnant breastfeed Have current primary AxisI disorder MDD Have use opioid agonist ( eg , codeine , oxycodone , tramadol , morphine ) opioid antagonist ( eg , naloxone , naltrexone ) within 14 day Have receive electroconvulsive therapy treatment within last 2 year , receive 1 course electroconvulsive treatment lifetime Have attempt suicide within past 2 year Have history intolerance , allergy , hypersensitivity buprenorphine opioid antagonist ( eg , naltrexone , naloxone ) Have significant blood loss blood donation within past 60 day Additional criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>